More about
Gynecologic Cancers
News
June 22, 2021
4 min watch
Save
VIDEO: Prolonged bevacizumab failed to improve survival in certain gynecologic cancers
In this video, Stephen C. Rubin, MD, professor and chief of the division of gynecologic oncology and Grotzinger-Raab Chair in Surgical Oncology at Fox Chase Cancer Center in Philadelphia, spoke with Healio about a study evaluating the optimal treatment duration of bevacizumab combined with carboplatin and paclitaxel in patients with primary epithelial ovarian cancer, fallopian tube cancer or peritoneal cancer.